Wang Angela L, Iadecola Costantino, Wang Gang
Premed Program, Washington University in St. Louis, St. Louis, MO, USA.
Feil Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.
J Geriatr Cardiol. 2017 Jan;14(1):67-72. doi: 10.11909/j.issn.1671-5411.2017.01.006.
Since the calcium channel blocker (CCB) has become one of the most prescribed agents for antihypertensive monotherapy in the world, this brief review will focus on the recent research and development of the dihydropyridine (DHP) CCB, addressing pharmacological mechanisms for the clinical efficacy of the third and fourth generations of the DHP CCBs, especially on their possible central mechanisms underlying lowering blood pressure.
由于钙通道阻滞剂(CCB)已成为全球最常用于抗高血压单一疗法的药物之一,本简要综述将聚焦于二氢吡啶(DHP)CCB的最新研究与开发,阐述第三代和第四代DHP CCB临床疗效的药理学机制,尤其是其降低血压的潜在中枢机制。